Author: IQ TIMES MEDIA
March 23 (Reuters) – U.S. drugmaker Pfizer and France’s Valneva said on Monday their experimental Lyme disease vaccine showed more than 70% efficacy in a late-stage trial.Pfizer said it had planned to seek U.S. regulatory approval for the vaccine called PF-07307405.There is currently no approved vaccine to prevent Lyme disease – spread by bites from infected blacklegged ticks – after GSK discontinued its Lymerix shot in 2002, citing insufficient consumer demand.While the Pfizer-Valneva vaccine showed 73.2% efficacy from 28 days after the fourth dose, it missed the primary goal in the first analysis due to fewer-than-anticipated Lyme cases being accrued…
While meeting with a venture capitalist last year, 16-year-old Rudrojas Kunvar received an offer that would excite even the most nonchalant teens: accept $300,000 to drop out of high school and run his AI startup full-time.”It was definitely a rough couple of weeks of contemplating,” Kunvar, who lives in Germantown, Maryland, told Business Insider. “That’s a lot of money.”Kunvar had spent the summer before building Evion, a free AI crop-analysis tool that uses images taken by basic camera drones that farmers can purchase themselves.The AI model analyzes images and generates a crop health map that farmers can integrate into their…
Last June, Taylor M. LaSane faced a decision she’d been weighing for years: whether to walk away from her six-figure salary at Google to go all in on the career coaching business she started three years earlier.Google had just offered voluntary buyouts to some US-based employees, including those in the finance organization where she worked, positioning the program as an option for workers who didn’t feel “all in” on the company’s direction.LaSane said her buyout offer included just under six months of severance pay. While the payout would help ease her transition to entrepreneurship, the risk was still significant. She…
March 23 (Reuters) – At least half a dozen Indian generic drugmakers launched cheaper versions of Novo Nordisk’s blockbuster diabetes drug Ozempic and weight‑loss drug Wegovy over the weekend, at globally unmatched prices and slashing treatment costs by about 70%.The patent for semaglutide, the active ingredient in Novo’s drugs, expired in India last week, paving the way for drugmakers to flood the market with dozens of brands.Analysts expect more than 40 Indian drugmakers to launch over 50 cheaper variants.Large Indian drugmakers are racing to capture a share of the global obesity market, projected to be worth about $100 billion by…
Amanda Peet is opening up about her breast cancer diagnosis, which she learned around the same time both of her parents were in hospice care.In a personal essay published Saturday in The New Yorker, the actress detailed the difficult period, sharing that she had long been monitored closely due to having “dense” and “busy” breasts, which require extra screening.“I had been seeing a breast surgeon every six months for checkups,” she wrote.Breast cancer deaths fall in US while women in poorer countries face rising risks, report findsAfter a routine scan in late August showed an unusual ultrasound result, Peet said…
RALEIGH, N.C. (AP) — For two hours, Claire Jefferies wanted to get away from the war in Iran and the rising gas prices and just commune with nature. And, so, she treated herself to a little forest bathing.“When I’m here, it’s almost like a protective bubble around me,” the human resources director said amid oaks and flowering magnolias at the J.C. Raulston Arboretum in Raleigh, North Carolina. “It provides a shield.”The Sunday morning session was led by certified forest therapy guide Shawn Ramsey. Jingling a tiny brass bell, she called her dozen or so charges to gather for meditation, breathing…
Nvidia’s GTC conference had everything: trillion dollar sales projections, graphics technology that can yassify video games, grand declarations that every company needs an OpenClaw strategy, and even a robot version of the beloved snowman Olaf from Disney’s “Frozen.” On the latest episode of TechCrunch’s Equity podcast, TechCrunch’s Kirsten Korosec, Sean O’Kane, and I recapped CEO Jensen Huang’s keynote and debated what it means for Nvidia’s future. And yes, a big part of our discussion focused on poor Olaf, whose microphone had to be turned off when he started rambling. Even if the demo had gone flawlessly, Sean might still have…
AI coding company Cursor launched a new model this week called Composer 2, which it promoted as offering “frontier-level coding intelligence.” However, an X user posting under the name Fynn soon claimed that Composer 2 was “just Kimi 2.5” with additional reinforcement learning — Kimi 2.5 being an open source model recently released by Moonshot AI, a Chinese company backed by Alibaba and HongShan (formerly Sequoia China). As evidence, Fynn pointed to code that seemed to identify Kimi as the model. “[A]t least rename the model ID,” they scoffed. It was a surprising revelation, since Cursor is a well-funded U.S.…
Elon Musk recently outlined ambitious plans for a chip-building collaboration between his companies Tesla and SpaceX. Bloomberg reports that Musk shared his plans on Saturday night at an event in downtown Austin, Texas, with a photo suggesting that what Musk is calling the “Terafab” facility will be built near Tesla’s Austin headquarters and “gigafactory.” Musk said he’s pursuing this project because semiconductor manufacturers aren’t making chips quickly enough for his companies’ artificial intelligence and robotics needs: “We either build the Terafab or we don’t have the chips, and we need the chips, so we build the Terafab.” The goal is…
An anonymous Substack post published this week accuses compliance startup Delve of “falsely” convincing “hundreds of customers they were compliant” with privacy and security regulations, potentially exposing those customers to “criminal liability under HIPAA and hefty fines under GDPR.” Delve is a Y Combinator-backed startup that last year announced raising a $32 million Series A at a $300 million valuation. (The round was led by Insight Partners.) On Friday, the startup attempted to refute the accusations on its blog, calling the Substack post “misleading” and saying it “contains a number of inaccurate claims.” The Substack post is credited to “DeepDelver,”…